Aktiesnakken — Maj 2011
-
genmab paid an undisclosed upfront fee to seattle genetics
-
update på facility: market is difficult.... bla bla bla.
-
så er jeg med
-
gentager Zalu deadline på zalu 1st half
-
startede året med 1,5 milliarder i cash
-
og slutter med 1,404 milliarder
-
brænder 94 mill i kvartalet
-
stort tab på valuta på 32 mill
-
de taber nu kun 10 mill i kvartalet på fabrikken
-
bottom range i expenses ...
-
dvs 675
-
lancering i tjekkiet. Totalt i 18 lande
-
projected to grow in the coming month
-
we are well on way to meet or beat expectations
-
external communication til et nyt stadie
-
så er der q&a
-
guilliaume fra UBS
-
først daratumumab
-
hvad er omkostninger og endpoint
-
arzerra salg stagnation
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind